AlphAIAlphAI — Financial news for AI agents
SEC EDGARMAY 271 min read$CODX

Egan Dwight H sold (to issuer) $8K of CODX

Egan Dwight H (Chief Executive Officer) sold (to issuer) 1,633 shares of Co-Diagnostics, Inc. (CODX) at $5.07 on 2026-05-23.

Original reporting
SEC EDGAR · Egan Dwight H
Published May 27, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CODX
Neutral
medium confidence
Mentioned
$CODX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CODXNeutralLow
01

Why it matters

The CEO’s sale to the issuer at a stated price is a disclosure event; without accompanying business updates, it is unlikely to materially change valuation expectations.

02

Market read

Traders may note insider activity, but the issuer-sale structure and lack of additional news keep the signal weak.

03

What to watch

No 10b5-1 plan is indicated, but the transaction is still to the issuer, which can reflect pre-arranged corporate processes rather than market timing.

Relevance 6/10Timing: Immediate (today’s SEC Form 4 filing), but unlikely to drive sustained repricing without other catalysts.

Background

The article is a SEC Form 4 insider transaction disclosure for Co-Diagnostics, Inc. (CODX).

Company-level read

Ticker impact

$CODXNeutralMedium confidence
Context

Co-Diagnostics CEO Egan Dwight H sold 1,633 shares to the issuer at $5.07/share, disclosed via SEC Form 4.

Expected impact

Likely limited near-term impact; any move would be more about liquidity/positioning than new company information.

Evidence & confidence

The filing is ownership-change disclosure without accompanying operational or financial catalysts; transaction code D suggests issuer involvement rather than open-market bearishness.

Market effects

Sector

Minimal; no sector-wide regulatory, trial, or commercial update is provided.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If code D reflects a structured issuer buyback/employee liquidity mechanism, the sale may be routine and not a bearish signal.

Key entities

  • issuer
    Co-Diagnostics, Inc.

    Company whose CEO insider sale to the issuer is disclosed on SEC Form 4.

  • insider
    Egan Dwight H

    Chief Executive Officer and director reporting the sale of 1,633 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CODX insider trading history →

Related articles

AUG 13
$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue was $0.17M vs $0.16M a year earlier. Operating loss was $6.2M, net loss $6.3M ($1.46/share). Cash was $3.6M. The company said it completed studies and submitted a 510(k) for its Flu A/B and RSV multiplex test, and raised $3.0M via private placement.

prnewswire.com6 min
AUG 13
$CODXMed

Co-Diagnostics, Inc. (CODX): Results of Operations and Financial Condition

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Co-Diagnostics Reports Second Quarter 2026 Financial Results Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-

SEC EDGAR 8-K6 min
AUG 13
$CODXMed

Co-Diagnostics submits flu/RSV test after study of more than 1,400 patients

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 revenue of $0.17 million, up from $0.16 million a year earlier, with a net loss of $6.3 million ($1.46/share) versus a $7.7 million loss in Q2 2025. Cash fell to $3.6 million from $11.9 million. The company said it completed studies for an FDA 510(k) and CLIA waiver for its Flu A/B & RSV PCR test and raised $3.0 million in a private placement.

stocktitan.net6 min
AUG 6
$CODXMed

Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test

Co-Diagnostics (Nasdaq: CODX) said it submitted a Dual 510(k) premarket notification with a concurrent CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument. The filing follows clinical studies of 1,400 symptomatic patients and analytical work across 27 studies and 10,000+ PCR runs. If granted, the CLIA waiver would enable decentralized point-of-care use; the platform is not yet for sale.

prnewswire.com2 min
MAY 29
$SPRCMedAI 8/10

Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest

SciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.

rttnews.com6 min